Medtronic has officially named its diabetes business “MiniMed”, marking a significant step in its planned separation of the unit. This move, first announced in May 2025, is part of Medtronic’s strategy to streamline operations and focus on high-growth, high-margin markets. By spinning off its diabetes division, Medtronic aims to create a dedicated, innovation-driven company with a clear mission to advance diabetes care.
The decision to choose MiniMed pays homage to the brand's legacy. Medtronic acquired the original MiniMed for $3.7 billion nearly 25 years ago, and has continued to use the name for its insulin pump systems. The new MiniMed will carry forward this trusted brand, which has a 40-year history of pioneering technologies in insulin delivery.
Que Dallara, current EVP and President of Medtronic Diabetes, will serve as CEO of the new MiniMed. “We’re thrilled to honor this rich 40-year legacy with a name that carries deep meaning and trust,” she said, emphasizing the company’s commitment to making diabetes more predictable and manageable.
The spin-off is expected to be completed within 18 months, primarily through an IPO followed by a split-off. The transaction is planned to be tax-free for U.S. shareholders. Once independent, MiniMed will remain headquartered in Northridge, California, and will continue operations with a team of over 8,000 employees. It currently contributes around 8% of Medtronic’s revenue and 4% of segment operating profit.
MiniMed’s product portfolio includes automated insulin pumps, smart insulin pens, and continuous glucose monitors (CGMs). A key pipeline development includes its partnership with Abbott, aiming to integrate Abbott’s FreeStyle Libre CGMs with Medtronic’s MiniMed 780G pump and InPen smart insulin system. In April 2025, the interoperable pump was submitted to the FDA.
Beyond the Abbott partnership, Medtronic has also expanded its proprietary CGM offerings. In May, the FDA approved its Simplera Sync CGM, designed for use with the MiniMed 780G. This complements the existing Guardian 4 and Simplera platforms, as part of a comprehensive diabetes ecosystem.
Looking ahead, MiniMed plans to further enhance its pipeline with next-generation technologies, including a patch pump, reaffirming its commitment to innovation and patient-centric diabetes care.